Signals elicited by TLRs following the detection of microbes are integrated and diversified by a group of four cytoplasmic adaptor molecules featuring an evolutionarily conserved Toll/IL-1R signaling domain. Single nucleotide polymorphisms (SNPs) in TLRs and their adaptor molecules have been shown to influence susceptibility to a range of infectious and other diseases. The adaptor MyD88 adaptor-like (Mal)/Toll/IL-1R–containing adaptor protein is involved in TLR2 and 4 signal transduction by recruiting another adaptor molecule, MyD88, to the plasma membrane. In this study, we used naturally occurring variants of Mal as tools to study the molecular biology of Mal in more detail in cellular model systems and to thereby identify functionally interesting variants whose corresponding nonsynonymous SNPs might be of further epidemiological interest. Of seven reported variants for Mal, we found Mal D96N associated with reduced NF-κB signaling and cytokine production after overexpression in HEK293 and Huh-7 cells. The D96N mutation prevented Mal from recruiting its signaling partner MyD88 to the plasma membrane and altered posttranslational modification of Mal. These findings led us to investigate the frequency of heterozygosity for the corresponding SNP rs8177400 in a Caucasian case-control study on the etiology of lymphoma, a disease in which TLRs have been implicated. Although rs8177400 did not modify lymphoma risk in general, its frequency of heterozygosity was accurately determined to 0.97%. Our data add rs8177400 (D96N) to the list of functionally important variants of Mal and warrant further research into its immunological, epidemiological, and diagnostic relevance.
In mammals, innate immunity relies on TLR pathways for the detection of invading pathogens (1). TLRs are a family of germline-encoded pattern recognition receptors endowed with the capacity to recognize different pathogen-associated patterns (PAMPs) (1, 2). Upon PAMP recognition, TLRs trigger the production of proinflammatory cytokines and IFNs by transcriptional regulation and thus initiate and shape adaptive immune responses (3). Different TLRs possess specificity for diverse structural classes of pathogen molecules. For example, TLR2 is the receptor for bacterial lipopeptides and TLR4 detects bacterial LPS (1). TLRs engage PAMPs in the extracellular space or endosomes and their cytoplasmic Toll/IL-1R (TIR) domains relay signals intracellularly where they are integrated and diversified by four adaptor molecules that share the evolutionarily conserved TIR domain (1, 4, 5). The first TLR adaptor to be discovered, MyD88, transduces signals emanating from IL-1R, IL-18R, and all TLRs except TLR3 (5). For optimal TLR2 and TLR4 MyD88-dependent signaling, MyD88 adaptor-like (Mal) (6), also known as TIR domain-containing adaptor protein (7), was shown to act as a “bridging molecule” that recruits MyD88 to the plasma membrane (8). Mal/MyD88-dependent signaling pathways involve the recruitment and activation of IL-1R–associated kinase (IRAK)-4, IRAK-1, and TNFR-associated factor-6. Subsequent signaling events culminate in the activation of the NF-κB, AP-1, and IFN regulatory factor-3, -5, or -7 transcription factors. This in turn initiates the expression of a multitude of inflammatory downstream genes (reviewed in Ref. 5).
Human Mal is a 25-kDa protein that undergoes posttranslational modification, for example, proteolytic cleavage by caspase-1, tyrosine phosphorylation by Bruton’s tyrosine kinase, and suppressor of cytokine 1-mediated ubiquitination, which seem to modulate Mal expression and activity by hitherto largely unknown mechanisms (5, 9). Mal contains several functional domains (see Fig. 1A): a phosphatidylinositol 4,5-bisphosphate (PIP2) binding motif (residues 15–35) required for its role as a bridging molecule (8); a PEST region (residues 35–72); and a TIR domain (residues 84–221) required for homotypic interactions with the MyD88, TLR2, and TLR4 TIR domains (6, 7, 10). TIR domains are highly conserved structurally (4), with structural similarity extending down to bacterial proteins, such as the Escherichia coli chemotaxis protein CheY (2). TIR domains consist of a central five-stranded, parallel β-sheet with five surrounding α-helices (nomenclature according to Ref. 4). The so-called BB loop, which connects strand βB with helix αB, has been highlighted as important for TIR-mediated signal transduction as mutations of a conserved BB loop proline to histidine abrogate signaling in TLRs and also Mal (P125H; Ref. 7).
Extremely rare point mutations in TIR adaptors have recently been linked to an increased susceptibility to infectious agents in affected human individuals (11). Similarly, single nucleotide polymorphisms (SNPs) in TLR signaling molecules have been associated with infectious, inflammatory, or autoimmune diseases (reviewed in Ref. 12). In Mal, rs7932766 (A186A), a variant in strong linkage disequilibrium with S180L, was recently shown to be associated with an increased susceptibility for tuberculosis in a small Vietnamese study (13), and heterozygous carriage of the nonsynonymous (amino acid-changing) Mal SNP (nsSNP), rs8177374 (S180L), was associated with substantial protection against invasive pneumococcal disease, bacteraemia, malaria, and tuberculosis in multiple populations and studies involving thousands of individuals (14). S180L was found protectively associated with tuberculosis in a Colombian (15) but not in a Russian (13, 16) study and with malaria in a Brazilian study (17). An association with systemic lupus erythematosus (15) but not rheumatoid arthritis has also been reported (13, 16). Overall, increasing evidence suggests that SNPs in Mal and other TLR signaling molecules may be considered important genetic determinants for disease. Unfortunately, most studies have not addressed the functional and structural consequences of these naturally occurring, nsSNP-associated phenovariants on the molecular level.
In this study, we used naturally occurring variants as probes to study the biology of the adaptor molecule Mal in more detail, with a view of identifying variants whose corresponding nsSNPs might be of epidemiological interest due to an interesting functional phenotype.
Materials and Methods
Reagents and cells
Reagents were from Sigma-Aldrich (St. Louis, MO) unless otherwise stated. HEK293 cells (A. Dalpke, Department of Hygiene and Medical Microbiology, University of Heidelberg, Heidelberg, Germany) were cultured in DMEM supplemented with 10% FCS, l218) were cultured as above. TLR2 and 3 ligands were from Axxora (Lörrach, Germany).
Cloning and site-directed mutagenesis
N-terminal hemagglutinin (HA; YPYDVPDYA) and myc (EEQKLISEEDL)-tag encoding oligonucleotides were inserted into pcDNA3.1(+), and subsequently, a Mal or MyD88-encoding PCR product was inserted, respectively. Template plasmids (U. Hasan, International Agency for Research on Cancer, Lyon, France) contained human Mal (235-aa isoform; accession number AF406652) or MyD88 (accession number U70451). Point mutations corresponding to Mal nsSNPs were introduced (QuikChange II Kit; Stratagene, La Jolla, CA) and verified by automated DNA sequencing. Mutated Mal inserts were back-cloned into the original backbones to avoid unwanted mutations. PCR and mutagenesis primer sequences are listed in Supplemental Table III.
Signaling assays, IL-8 ELISA, and quantitative real-time PCR
HEK293 cells in 24-well plates (7.5 × 104
Confocal immunofluorescence microscopy
HEK293 and Huh-7 cells seeded on poly-l2 (see above). Images taken using widefield (for tilescans; on a Zeiss Cell Observer, ×40) or confocal (for analysis images and live cell imaging on a Leica SP5, ×40–63) microscopy with sequential scanning were processed using Leica LAS AF Lite or Zeiss AxioVision software.
Coimmunoprecipitations and expression analysis by one-dimensional SDS-PAGE
HEK293 cells seeded in 10-cm dishes (1.5 × 106
Two-dimensional gel electrophoresis
Sequence alignments, homology modeling, and structural analysis
Protein sequences were from Swiss-Prot (www.expasy.ch), and alignments were color-formatted according to amino acid physicochemical properties (Joy server: tardis.nibio.go.jp/joy). Homology modeling was based on the MyD88 TIR domain nuclear magnetic resonance structure (Protein Data Bank code: 2js7; Ref. 19). Sequence alignments were generated using ClustalX, manually optimized and subjected to Modeler (20). GROMACS, ANOLEA, VERIFY_3D, and ERRAT were used to improve and score models for energy and sterical correctness (see Supplemental Table II), respectively. Pymol and Adaptive Poisson-Boltzmann Server were used for structure analysis and surface charge calculations (see Ref. 21 for software citations).
Study population: German multicenter case-control study on the etiology of lymphomas
A population-based case-control study approved by the local ethical committees was carried out from 1999 to 2002 in six regions of Germany among 18- to 80-y-old adults, 1:1 matched for gender, age (±1 y of birth), and study region (for details, see citations in Ref. 22). The study comprises 710 case-control pairs, including 554 cases of B-non-Hodgkin’s lymphoma, 158 cases of diffuse large B cell lymphoma, 92 cases of follicular lymphoma, 104 cases of B cell chronic lymphatic leukemia, 76 cases multiple myeloma, 29 cases of MALT lymphoma, 35 cases of T-non-Hodgkin’s lymphoma, and 115 cases of Hodgkin’s lymphoma. One case was diagnosed as Hodgkin’s lymphoma and non-Hodgkin’s lymphoma. Controls were drawn randomly from population registers of the study regions. Written informed consent was obtained from each subject.
Polymorphism information, analysis and genotyping
A list of reported SNPs in human TIRAP (Gene ID: 114609), was obtained from National Center for Biotechnology Information at www.ncbi.nlm.nih.gov (Supplemental Table I). HapMap data were from www.hapmap.org (23). Genotyping was performed by pyrosequencing as described previously (22). PCR mixtures contained: 5 ng DNA, 1× Ready Mix PCR buffer (ABgene, Epsom, U.K.), 0.25 U of Thermoprime DNA polymerase (ABgene), deoxynucleoside triphosphates, each at 167 μM (PeqLab, Erlangen, Germany), and primers (3 pmol each) in a total reaction volume of 12 μl. Cycling conditions 36 cycles, 94°C 40 s, 57°C 40 s, and 72°C 40 s. For primers, see Supplemental Table III.
Statistical analysis of association study
For signaling assays, p values were determined using the Student t test; *p < 0.01 and **p < 0.05. For genotyping studies, unconditional logistic regression models adjusted for age, sex, and study center were used to obtain odds ratios as estimates of relative risk. Genotype was coded as an ordinal variable based on the number of rare alleles (0, 1, 2) and as a binary variable assuming dominant inheritance. The reference group for genotype analyses was the wild-type (WT) homozygous genotype in controls. Analysis was preformed with SAS version 9.
Mal D96N is a loss-of-function variant of TIRAP
Of >100 SNPs reported in the human TIRAP gene region on chromosome 11 (Location: 11q24.2), 7 nsSNPs map to its coding region and lead to an amino acid exchange in the Mal protein (Supplemental Table I): A9P and R13W (N-terminal domain), S55N (PEST region), D96N, S180L, V197I (TIR domain), and X222W, which converts a STOP codon into a tryptophan codon, leading to a longer isoform of Mal (Fig. 1A). We considered these naturally occurring variants as interesting probes to gain insights into the biology of Mal and concentrated on the six reported nsSNPs leading to point mutations (X222W was not investigated in this study). Initially, amino acid conservation in the location of these SNPs was analyzed by carrying out sequence alignments of Mal protein orthologs from human to Xenopus (Supplemental Fig. 1). We found that all six amino acids in question are highly conserved in mammals. Mal D96 is even conserved from humans to nonmammalian species, such as chicken and Xenopus, suggesting that it may be of high functional or structural importance.
To study the naturally occurring variants of Mal functionally, corresponding expression constructs were generated. Mal P125H was included in some experiments for comparison (7). Although D96N and P125H expressed at slightly lower levels, other myc-tagged mutant constructs expressed similarly to WT Mal (Fig. 1B). We next investigated whether overexpression of the Mal variants would lead to NF-κB activation on a level similar to WT by dual luciferase reporter assays in HEK293 cells. As shown in Fig. 1C, most Mal variants reproducibly exhibited levels of NF-κB reporter activation comparable to WT (S55N, S180L, and V197I) or slightly attenuated (A9P and R13W). Interestingly, NF-κB activation was completely abolished for Mal D96N. We also measured the production of secreted IL-8 from Mal-transfected cell cultures by ELISA. Similarly to NF-κB activation, most mutants produced IL-8 to a similar level as Mal WT as a consequence of Mal overexpression (Fig. 1D). Again, the R13W mutant was showing a reduction in IL-8 production. Most strikingly, IL-8 production was severely diminished for D96N, suggesting that this variant is impaired in downstream signaling. This was also confirmed at the level of IL-8 and TNF-α mRNA induction as analyzed by quantitative real-time PCR (Fig. 1E). We consistently observed signaling comparable to WT for Mal S180L (cf. Ref. 14) in all assays in the HEK293 system (Fig. 1C–E). Similar results were obtained for D96N and S180L in Mal signaling assays in Huh-7 cells (Fig. 1F). To investigate whether D96N could influence the ability of WT Mal protein to signal, we performed NF-κB dual luciferase assays and measured IL-8 production by ELISA in HEK293 cells cotransfected with increasing amounts of D96N and a constant amount of WT Mal. Mal P125H was used as a dominant-negative control (7). As shown in Supplemental Fig. 2A and 2B, increasing plasmid amounts of D96N moderately but dose-dependently decreased NF-κB activity and secreted IL-8 levels, indicating that Mal D96N may modulate Mal-dependent signaling pathways if expressed in excess. In contrast, TLR2-dependent NF-κB signaling, which relies on Mal, was not markedly affected in the HEK293 system (Supplemental Fig. 2C, 2D). In the following, we focused our studies on the D96N variant. Considering lower expression levels an incomplete explanation, we conducted a series of functional and structural analyses to investigate the molecular basis for the observed inability of D96N to initiate NF-κB signaling.
Plasma membrane trafficking and recruitment of MyD88 are impaired for Mal D96N
We initially hypothesized whether the ability of Mal to engage in signaling complexes could be compromised in Mal D96N. Mal signaling as a result of overexpression is strictly MyD88 dependent as confirmed by experiments in MyD88-deficient HEK293 cells (18) (data not shown). In normal HEK293 cells, Mal overexpression leads to NF-κB activation. We therefore concentrated on signaling events downstream of TLR2 and TLR4 and initially analyzed the ability of Mal to self-associate as shown earlier (10). We cotransfected HA-Mal WT or D96N and myc-Mal WT or D96N into HEK293 cells and analyzed protein complexes by immunoprecipitation and immunoblot. As evident from Fig. 2A, Mal D96N was able to interact with Mal WT and Mal D96N, suggesting that oligomer formation was not compromised. Cotransfecting HA-Mal WT or D96N and myc-MyD88, we investigated next whether Mal D96N could still engage its signaling partner MyD88 as reported previously for WT Mal (7, 10). Fig. 2B illustrates that interactions for Mal D96N with MyD88 were similar to Mal WT. Because D96N appeared not to affect molecular interactions of Mal, we sought to address by immunofluorescence confocal microscopy whether Mal D96N trafficked differently to WT in transfected HEK293 cells. Fig. 2C shows staining for myc-Mal WT at the plasma membrane, in addition to some cytoplasmic staining. In Mal D96N-transfected cells, cytoplasmic staining was also visible and appeared more (condensed) punctate. Compared with WT Mal, staining along the plasma membrane was less pronounced for Mal D96N. This was verified using z-stack analysis of individual cells (data not shown). In cotransfections of both myc-Mal WT and HA-D96N, the two proteins partially colocalized intracellularly and (to a lesser degree) at the plasma membrane (Fig. 2D and insets), which is in keeping with our coimmunoprecipitation studies. We next investigated the redistribution of overexpressed MyD88 from distinct cytoplasmic foci to a more uniform intracellular distribution and localization to the plasma membrane, which was observed as a result of Mal coexpression (8). As Fig. 2E shows, in the majority of cells (>65%), MyD88 located to cytoplasmic foci in the absence of Mal but was redistributed across the cytoplasm and membrane-proximally as expected when Mal WT was coexpressed (Fig. 2F). In membrane-proximal areas, myc-Mal and HA-MyD88 partially colocalized. When D96N was expressed (Fig. 2G), MyD88 showed the same focal staining observed in single transfections of MyD88 (Fig. 2E) and was not redistributed across the cytoplasm or to the plasma membrane. At the observed cytoplasmic foci, MyD88 and Mal D96N showed colocalization (as verified by two-dimensional scatter plot analysis), suggesting that the interaction shown earlier (Fig. 2B) occurs at these sites. This was confirmed by analysis of wide field tilescans (data not shown) and in Huh-7 using both Ab staining in fixed cells (Fig. 2E–G) and live cell imaging (Fig. 2H). In conclusion, our data therefore suggest that although Mal D96N and MyD88 physically interact, this complex is unable to reach the plasma membrane.
D96 influences posttranslational modification of Mal
To further assess the structural basis for the inability of D96N Mal to signal, we generated three-dimensional homology models of the Mal WT and D96N TIR domains based on the nuclear magnetic resonance structure of the MyD88 TIR domain (19) and subjected it to a 10-ns molecular dynamics simulation (Materials and Methods). Tertiary structure and surface charge were subsequently analyzed in both models. Fig. 3A shows that the structures of Mal WT and D96N are relatively similar with regard to their tertiary structure but differ in the spatial arrangement of several flexible loops (particularly EE loop) that connect the main secondary structure elements. Several loops (BB, AA, and CC) meet at a surface region in which residue 96 is located in the AA loop of the molecule in proximity to the BB loop (Fig. 3B and Supplemental Fig. 3). The WT model features a highly negatively charged surface formed by D96, two adjacent glutamic acid residues, E94 and E95 (AA loop), D102 (αA), and D122 (BB loop). This charged patch is much less pronounced in the D96N model (Fig. 3A). To investigate whether this effect on surface charge could contribute to the observed loss of function, we mutated aspartic acid 96 to glutamine (a residue equivalent to asparagine in D96N, therefore expected to result in charge reversal like the D96N amino acid exchange), arginine (to alternatively reverse charge), or glutamic acid (the equivalent of aspartic acid to maintain a negative charge; predicted in Fig 3B). The expression of these charge-affecting mutants was verified by immunoblot (Fig. 3C) and their signaling properties by NF-κB dual luciferase assay. Fig. 3D shows that, expectedly, D96Q and D96R were completely defective in signaling, which would unlikely be accounted for by the observed slight differences in expression level. Surprisingly, D96E, a conservative substitution predicted to maintain the negative charge, also resulted in complete loss of function and the charge introduced by the gamma-carboxyl group of glutamate appeared not to restore signaling to WT levels. We wondered whether the low tolerance for substitution at position 96 hinted to a more distinct functional role for D96 and whether its mutation might affect reported posttranslational modifications of Mal that could regulate its activity and/or trafficking (5). Therefore immunoprecipitates from myc-tagged WT, D96N-, and D96E-transfected cells were analyzed by two-dimensional gel electrophoresis combined with immunoblot. The myc-Mal WT blot (Fig. 3E, panel 1) repeatedly (n = 5) showed that Mal WT existed as a range of different species (cf. orange signals in panels 4 and 5), which is indicative of posttranslational modification. In the D96N blot (Fig. 3E, panel 2), several spots observed for Mal WT were clearly absent (marked by asterisks in panel 5). This was not linked to lower expression of D96N and was also observed for D96E (data not shown). When probing for Mal tyrosine phosphorylation (9), we observed clear differences in the number and relative abundance of different species (Fig. 3F). This strongly suggested that mutations at D96 influence the posttranslational modification of Mal.
Mal D96N occurs heterozygously in ∼1% of Europeans
Because our data showed that the reported naturally occurring variant D96N in human TIRAP results in a loss of function in the Mal protein, we sought to obtain a first impression of the potential epidemiological relevance of the corresponding SNP rs8177400. As polymorphisms in several TLRs have been associated with certain subtypes of lymphoma (22, 24), we decided to genotype rs8177400 in 665 cases and 678 age, sex, and area matched population-based controls of a German case-control study on the etiology of lymphoma (22). We found 13 heterozygous individuals—6 (0.9%) in controls and 7 (1.03%) in lymphoma patients. Among the patients, heterozygotes were found in 1 of 9 precursor B cell non-Hodgkin’s lymphoma, 2 of 101 follicular lymphoma, 2 of 104 chronic lymphocytic leukemia, 1 of 105 Hodgkin’s lymphoma, and 1 of 72 other B cell non-Hodgkin’s lymphoma patients. No homozygous A/A genotypes were detected. Overall the frequency of heterozygosity for rs8177400 was 0.97% in this Caucasian study population. Lymphoma risk in general was not modified in association with rs8177400, although statistical power was limited.
In this study, we sought to address the question whether known naturally occurring variants of Mal influence the function of this important signaling adaptor, and if so, which changes on the molecular level were responsible for the observed phenotype. Our aim was also to thereby identify such variants that might be potentially important genetic determinants for disease susceptibility or progression in humans.
Of seven reported nsSNPs in human TIRAP, D96N (rs8177400) was identified to be defective in initiating signaling in HEK and Huh-7 cells, as assessed by NF-κB activation and cytokine mRNA induction and secretion (Fig. 1). The data we obtained for D96N in the HEK293 system allow assessing the ability of this TIR adaptor variant to signal downstream receptor-independently. Although one might have expected that defective signaling could be a direct impairment of these molecular interactions, our experimental data show that Mal D96N is still able to interact with Mal WT itself and with MyD88 in coimmunoprecipitation experiments (Fig. 3) and confocal microscopy analyses (Fig. 2). Structural modeling placed the D96N mutation into a structural framework and predicted a reversal of charge as a result of this amino acid exchange. Instead of being mainly dependent on charge (10), TIR-TIR interactions of MyD88 and Mal may thus not be as dependent on charge as previously proposed rather on direct and specific interactions of surface residues as suggested earlier (4). In fact, D96 is not only conserved in different species but also different TIR proteins (cf. Supplemental Fig. 1), for example. We noted that the positioning of acidic residues E94, E95, D96, and D154 resembled that of D12, D13, and D57 in the structural relative of Mal, CheY (2, 25) (see Supplemental Fig. 3). In CheY, these aspartates form an acidic pocket important for Mg2+ coordination and phosphorylation of D57 that acts as a conformational switch (25, 26). Structural studies outside the scope of this present report may help elucidate whether D96 in Mal plays as similar role and orchestrates TIR conformation, possibly by influencing BB loop conformation. Our two-dimensional gel electrophoresis data clearly show that the D96N mutation does affect posttranslational modification of Mal. In fact, several phosphotyrosine-positive acidic Mal species are absent in D96N (cf. Fig. 3F, species 3–5) or differently abundant (cf. species 1 and 2). This could be indicative of actual changes in Mal tyrosine phosphorylation, which was reported to occur at Y86, Y159, and Y106 (9), the latter being structurally most proximal to D96. Although the precise nature and location of modification needs to be determined, the occurrence of differently charged species of similar m.w. (asterisks in Fig. 3E) is indicative that D96N may affect phosphorylation as charge and thus the isoelectric point would primarily be altered. In vitro phosphorylation assays or purifying Mal WT and D96N proteins and comparing peptide fingerprints by mass spectrometry may be ways to address this question in detail. TIR adaptor posttranslational modifications apart from phosphorylation include ubiquitinylation and proteolytic cleavage in Mal, and myristoylation in TIR domain-containing adaptor molecule-2, another bridging adaptor (5). Mass spectrometry may be able to address whether these or other modifications correspond to the so far unassigned spots observed in the Mal WT sample.
At this point, it is difficult to assess whether or to which extent the change in posttranslational modification is linked to the inability of Mal D96N to traffic and redistribute MyD88, a simultaneous observation we made. In a cellular setting, the presence of D96N would thus result in the failure of Mal-MyD88 complexes to reach the plasma membrane where MyD88 would engage other signaling components. Our findings confirm that correct membrane targeting of Mal is strictly required for proper signaling as shown earlier by removal of the membrane-targeting PIP2 binding motif or mutation of conserved lysines that are believed to interact with the negatively charged surface of lipid membranes (8). D96 is distal from the PIP2 motif in sequence (aa 15–35) and located in the TIR domain of Mal. Determinants other than the PIP2 motif thus also seem to influence Mal trafficking and MyD88 recruitment toward the membrane. Posttranslational modifications, which are influenced by residues such as D96, may be such determinants. Potentially only correctly modified Mal-MyD88 complexes may be able to enter the appropriate trafficking routes that remain elusive. Alternatively, it is also conceivable that D96 as a surface residue may allosterically regulate (see above) or even directly contact the Mal N terminus. This would be reminiscent of the interaction of the N-terminal PIP2 motif in phosphatase and tensin homolog (PTEN) with its C terminus (27). In fact, in PTEN phosphorylation events in the PTEN C terminus modulate PIP2 binding and thus membrane interaction.
With regard to phenovariants of Mal other than D96N, the A9P, S55N and V197I nsSNP mutations appeared to have no influence Mal signaling. R13W (rs8177399) was attenuated in NF-κB activation and IL-8 secretion, and it may be interesting to characterize this phenovariant of Mal more fully. R13 is located in close proximity to the PIP2 motif and may thus have a more direct effect on Mal trafficking. Mal S180L (rs8177374 in human TIRAP) was previously identified as a sequence variant attenuated in signaling using a different experimental approach (14). In genetic complementation assays in Tirap-deficient mouse embryonic fibroblasts, a Mal S180L construct was unable to reconstitute signaling to TLR2 ligands. Mal S180L failed to bind TLR2 but interacted normally with MyD88 and itself in GST pulldowns. In this study, we have evaluated signaling in HEK293 and Huh-7 cells and consistently found that Mal S180L signaled like WT using different readouts. Taken together, these independent sets of data would suggest that Mal S180L is unable to assist in transducing incoming TLR signals in a genetic complementation setting but can transduce downstream signals normally as assessed by overexpression.
The functional data presented here warrant the next logical steps to determine the relevance of D96N (rs8177400), S180L (rs8177374), and possibly R13W (rs8177399) on susceptibility to or protection against disease in humans, for example, the analysis of cytokine profiles in heterozygous or even homozygous carriers upon stimulation with different TLR agonists. It was suggested that dampened cytokine responses leading to a reduced pathology might explain the protective association of S180L heterozygosity with invasive pneumococcal disease, bacteraemia, malaria, and tuberculosis (14). In the HEK293 system, TLR2-dependent signaling was unaffected by D96N and MalWT-induced signaling only at a molar excess of D96N (Supplemental Fig. 2). Our data tentatively suggest that, depending on their relative abundance, Mal D96N may be able to modulate Mal WT-dependent signaling, a question requiring clarification in cells isolated form D96N carriers. Similar studies proved insightful in patients carrying rare MyD88 (11) or IRAK-4 (28) mutations. Whereas mutations resulting in no or subtle functional consequences may escape negative selective pressure (e.g., TLR4 D299G, T399I; Ref. 29, mutations that severely compromise function would probably not be maintained in a population exposed to microbial pathogens, unless heterozygosity resulted in a protective phenotype). D96N rs8177400 G722 > A had been found heterozygously in small African-American (0 of 44; 0%) and European (2 of 46; 4.3%) collections, and the HapMap “Tuscans in Italy” population (1 of 77; 1.2%) and “Han Chinese in Beijing” (1 of 82; 1.2%) populations (Supplemental Table I and Ref. 23) but was not polymorphic in a small Vietnamese study population (n = 45; Ref. 13). Our genotyping studies confirm previous preliminary studies and demonstrate that the frequency of heterozygosity of D96N is 0.97% in a Caucasian population. Further preliminary studies in other ethnic groups show that Mal rs8177400 (D96N) also occurs in non-Caucasians with low (<1%) frequency (A. Rautanen, T.C. Mills, A.V.S. Hill, and A.N.R. Weber, unpublished data) in keeping with HapMap data (23). These studies would need to be extended to determine the frequency of this nsSNP in non-Caucasian populations more accurately. Our analyses on the influence of s8177400 (D96N) on the etiology of lymphoma remain inconclusive because of low statistical power, but the combined epidemiological and functional data warrant the inclusion of rs8177400 into future genetic association studies with larger sample sizes. Focusing such studies on already functionally characterized nsSNPs such as rs8177400 (D96N), rs8177374 (S180L), or rs8177399 (R13W) may not only prove fruitful for unraveling further genetic associations with disease but also cost-effective. Further studies systematically investigating the relevance of naturally occurring mutations in other adaptors or pattern recognition pathways may prove insightful both to understand the molecular biology of these molecules more fully as well as to uncover further genetic variants that may profoundly affect disease outcome.
We thank A. Dalpke and A. Bowie for critical reading of this manuscript. We thank J. Meckler, M. Scheuermann, J. Hess, W. Rittgen, M. Schnölzer, M. Brom, and F. Bestvater for technical assistance. We also thank W. von der Lieth, M. Frank, and T. Holz for support regarding molecular dynamics and computers. S.D.G.
Disclosures The authors have no financial conflicts of interest.
This work was supported by German Research Foundation Grant We4195-1 and the German Cancer Research Center (to J.G., A.V.K., E.C., and A.N.R.W.). A.N. was funded by José Carreras Leukemia Foundation Grants DJCLS-R04/08 and 07/26f. A.R. was funded by the European Union FP6 GRACE grant and the Academy of Finland. T.C.M. was funded by the Wellcome Trust, and A.V.S.H. is a Wellcome Trust Principal Fellow.
The online version of this article contains supplemental material.
Abbreviations used in this paper:
- heavy chain
- human embryonic kidney
- IL-1R–associated kinase
- light chain
- MyD88 adaptor-like
- nonsynonymous single nucleotide polymorphism
- pathogen-associated molecular pattern
- phosphatidylinositol 4,5-bisphosphate
- phosphatase and tensin homolog
- single nucleotide polymorphism
- Received April 9, 2009.
- Accepted January 7, 2010.
- Copyright © 2010 by The American Association of Immunologists, Inc.